Combining cancer vaccines with chemotherapy

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 16, 2005, Pages 2813-2820

  Chong, Gabriel ^a   Morse, Michael A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Fas ligand; Lymphopenia; Regulatory T cell; Suppressor T cell

Indexed keywords

ALPHA INTERFERON; ANTIIDIOTYPIC ANTIBODY; AZATHIOPRINE; BCG VACCINE; BUSULFAN; CANARY POX VACCINE; CANCER VACCINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DINITROPHENYLHAPTEN; DOCETAXEL; DOXORUBICIN; FLUDARABINE; FLUOROURACIL; GASTRIN 17 PLUS DIPTHERIA TOXIN; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IRINOTECAN; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; MUCIN 1; PACLITAXEL; RECOMBINANT GAMMA INTERFERON; TEMOZOLOMIDE; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE;

ANTIGEN EXPRESSION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CLINICAL TRIAL; COLON CARCINOMA; COLORECTAL CANCER; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; EFFECTOR CELL; GLIOMA; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; IN VITRO STUDY; LUNG CANCER; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTOPENIA; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA CELL; NATURAL KILLER CELL; NONHUMAN; OSTEOSARCOMA; RECEPTOR BINDING; REVIEW; SINGLE DRUG DOSE; SKIN TEST; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 29444433283     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.16.2813     Document Type: Review

References (57)

1. NYGREN P, SORBYE H, OSTERLUND P, PFEIFFER P: Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica. expert report. Acta Oncol. (2005) 44:203-217.
2. EMENS LA, JAFFEE EM: Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res. (2005) 65:8059-8064.
3. MITCHELL MS: Combinations of anticancer drugs and immunotherapy. Cancer Immunol. Immuother. (2003) 52:686-692.
4. TERANDO A, MULE JJ: On combining antineoplastic drugs with tumor vaccines. Cancer Immunol. Immunother. (2003) 52:680-685.
5. LAKE RA, ROBINSON BW: Immunotherapy and chemotherapy - a practical partnership. Nat. Rev. Cancer (2005) 5:397-405.
6. BLATTMAN JN, GREENBERG PD: Cancer immunotherapy: a treatment for the masses. Science (2004) 305:200-205.
7. TSIMBERIDOU AM, YOUNES A, ROMAGUERA J et al.: Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. Cancer (2005) 104(2):345-353.
8. SFIKAKIS PP, GOURGOULIS GM, MOULOPOULOS LA, KOUVATSEAS G, THEOFILOPOULOS AN, DIMOPOULOS MA: Age-related thymic activity in adults following chemotherapy-induced lymphopenia. Eur. J. Clin. Invest. (2005) 35:380.
9. TSAVARIS N, KOSMAS C, VADLAKA M, KANELOPOULOS P, BOULAMATSIS D: Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br. J. Cancer (2002) 87:21-27.
10. EMENS LA, REILLY RT, JAFFEE EM: Breast cancer vaccines: maximizing cancer treatment by tapping into host immunity. Endocrine-Related Cancer (2005) 12:1-17.
11. MACHIELS JPH, REILLY RT, EMENS LA et al.: Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. (2001) 61:3689-3697.
12. MANTHEY CL, PERERA PY, SALKOWSKI CA, VOGEL SN: Taxol provides a second signal for murine macrophage tumoricidal activity. J. Immunol. (1994) 152:825-831.
13. DUDLEY ME, WUNDERLICH JR, YANG JC et al.: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. (2005) 23:2346-2357.
14. BERD D, MAGUIRE HC Jr, MASTRANGELO MJ: Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res. (1984) 44:5439-5443.
15. PROIETTI E, GRECO G, GARRONE B et al.: Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J. Clin. Invest. (1998) 101(2):429-441.
16. LIVINGSTON PO, CUNNINGHAM-RUNDLES S, MARFLEET G et al.: Inhibition of suppressor-cell activity by cyclophosphamide in patients with malignant melanoma. J. Biol. Response Mod. (1987) 6(4):392-403.
17. ERCOLINI AM, LADLE BH, MANNING EA et al.: Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J. Exp. Med. (2005) 201:1591-1602.
18. SCHIAVONI G, MATTEI F, DI PUCCHIO T et al.: Cyclophosphamide induces Type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood (2000) 95:2024-2030.
19. LI L, OKINO T, SUGIE T et al.: Cyclophosphamide given after active specific immunization augments antitumor immunity by modulation of Th1 commitment of CD41 T cells. J. Surg. Oncol. (1998) 67:221.
20. LEVITT MI, KASSEM B, GOODING WE et al.: Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms. Lung Cancer (2004) 43:335-344.
21. NOWAK AK, ROBINSON BW, LAKE RA. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemoimmunotherapy. Cancer Res. (2002) 62:2353-2358.
22. CORREALE P, AQUINO A, GIULIANI A et al.: Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro. Int. J. Cancer (2003) 104:437-445.
23. VETVICKA V, VETVICKOVA J, SONNENFELD G: Effect of cytokines on 5-fluorouracil-mediated immunosuppression. Immunol. Lett. (1995) 47:103-106.
24. WEINER LM, HUDES GR, KITSON J et al.: Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen. Cancer Immunol. Immunother. (1993) 36(3):185-190.
25. SU YB, SOHN S, KROWN SE et al.: Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J. Clin. Oncol. (2004) 22:610-616.
26. ORSINI F, PAVELIC Z, MIHICH E: Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice. Cancer Res. (1977) 37:1719-1726.
27. HILGARD P, POHL J, STEKAR J, VOEGELI R: Oxazaphosphorines as biological response modifiers - experimental and clinical perspectives.Cancer Treat. Rev. (1985) 12:155-162.
28. EHRKE MJ, MACCUBBIN D, RYOYAMA K, COHEN SA, MIHICH E: Correlation between adriamycin-induced augmentation of interleukin 2 production and of cell-mediated cytotoxicity in mice. Cancer Res. (1986) 46:54-60.
29. MACCUBBIN DL, WING KR, MACE KF, HO RL, EHRKE MJ, MIHICH E. Adriamycin-induced modulation of host defenses in tumor-bearing mice. Cancer Res. (1992) 52:3572-3576.
30. TOMAZIC V, EHRKE MJ, MIRICH E: Augmentation of the development of immune responses of mice against allogencic tumor cells after adriamycin treatment. Cancer Res. (1981) 41:3370-3376.
31. MANTOVANI A, LUINI W, CANDIANI GP, SPREAFICO F: Effect of chemotherapeutic agents on natural and BCG-stimulated macrophage cytotoxicity in mice Int. J. Immunopharmacol. (1980) 2:333-339.
32. PRITCHARD-JONES K, SPENDLOVE I, WILTON C et al.: Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma. Br. J. Cancer (2005) 92:1358-1365.
33. HOLMBERG LA, OPARIN DV, GOOLEY T. SANDMAIER BM: The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope). Clin. Breast Cancer. (2003) 3(Suppl. 4):S144-S151.
34. TURK JL, PARKER D: Effect of cyclophosphamide on immunological control mechanisms. Immunol. Rev. (1982) 65:99-113.
35. NOWAK AK, ROBINSON BW, LAKE RA: Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. (2003) 63:4490-4496.
36. NOWAK AK, LAKE RA, MARZO AL et al.: Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J. Immunol. (2003) 170:4905-4913.
37. MITCHELL MS, KAN-MITCHELL J, KEMPF RA, HAREL W, SHAU HY, LIND S: Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res. (1988) 48:2883-5893.
38. MILES DW, TOWLSON KE, GRAHAM R et al.: A randomized Phase II study of sialyl-Tn and DETOX-B adjuvant with or without cydophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br. J. Cancer (1996) 74(8):1292-1296.
39. MAYORDOMO J, TRES A, MILES D, FINKE L, JENKINS H: Long-term follow-up of patients concomitantly treated with hormone therapy in a prospective controlled randomized multicenter clinical study comparing STn-KLH vaccine with KLH control in stage IV breast cancer following first-line chemotherapy. J. Clin. Oncol. (2004) 22(Suppl.) (Abstract 2603).
40. LAHERU DA et al.: A feasibility study of a GM-CSF secreting irradiated whole cell allogeneic vaccine (GVAX) alone or in sequence with cytoxan for patients with locally advanced or metastatic pancreatic cancer. Proc. Am. Assoc. Cancer Res. (2004) A54.
41. CASATI A, ZIMMERMANN VS, BENIGNI F, BERTILACCIO MT, BELLONE M, MONDINO A: The immunogenicity of dendritic cell-based vaccines is not hampered by doxorubicin and melphalan administration. J. Immunol. (2005) 174:3317-3325.
42. ERALP Y, WANG X, WANG JP, MAUGHAN MF, POLO JM, LACHMAN LB: Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res. (2004) 6(4):275-283.
43. TONG Y, SONG W, CRYSTAL RG: Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res. (2001) 61:7530-7535.
44. BERD D, SATO T, MAGUIRE HC Jr, KAIRYS J, MASTRANGELO MJ: Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J. Clin. Oncol. (2004) 22:403-415.
45. RAMANATHAPURAM LV, KOBIE JJ, BEARSS D, PAYNE CM, TREVOR KT, AKPORIAYE ET: α-Tocopheryl succinate sensitizes established tumors to vaccination with nonmatured dendritic cells. Cancer Immunol. Immunother. (2004) 53:580-588.
46. NIGAM A. YACAVONE RF, ZAHURAK ML et al.: Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. Int. J. Oncol. (1998) 12:161-170.
47. NIETHAMMER AG, WODRICH H, LOEFFLER M et al.: Multidrug resistance-1 (MDR-1): a new target for T cell-based immunotherapy. FASEB J. (2005) 19:158-159.
48. BERGMANN-LEITNER ES, ABRAMS SI: Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lyric sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes. Cancer Immunol. Immunother. (2001) 50:445-455.
49. YOSHIMOTO Y, KAWADA M, IKEDA D, ISHIZUKA M: Involvement of doxorubicin-induced Fas expression in the antitumor effect of doxorubicin on Lewis lung carcinoma in vivo. Int. Immunopharmacol. (2005) 5:281-288.
50. YANG S, HALUSKA FG: Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways. Immunol. (2004) 172:4599-4608.
51. LISSONI P, BRIVIO F, FUMAGALLI L et al.: Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int. J. Biol. Markers (2004) 19:135-140.
52. LIU G, AKASAKI Y, KHONG HT et al.: Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene (2005) 24(33):5226-5234.
53. VON MEHREN M, ARLEN P, GULLEY J et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin. Cancer Res. (2001) 7:1181-1191.
54. LAHERU D, BIEDRZYCKI B, JAFFEE EM: Immunologic approaches to the management of pancreatic cancer. Cancer J. (2001) 7(4):324-337.
55. THOMAS AM, SANTARSIERO LM, LUTZ ER et al.: Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J. Exp. Med. (2004) 200:297-306.
56. REECE DE, FOON KA, BHATTARCHARYA-CHATTERJEE M et al.: Use of the anti-idiotype breast cancer vaccine 11D10 in conjunction with autologous stem cell transplantation in patients with metastatic breast cancer. Clin. Breast Cancer. (2003) 3(Suppl. 4):S152-S157.
57. SHAPIRO J, MARSHALL J, KARASEK P et al.: G17DT+gemcitabine [Gem] versus placebo+Gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: results of a randomized, double-blind, multinational, multicenter study. Proc. Am. Soc. Clin. Oncol. (2005) LBA4012.